Table 2.
Histological characteristics of the patient population
| Hepatitis B patients | Hepatitis C patients | |||
| Liver biopsy features | Baseline liver biopsy | Liver Biopsy after treatment | Baseline liver biopsy | Liver Biopsy after treatment |
| HAI*1 | 8(3,13)*1 | 4 (0,12)*1 | 7 (2,14)*1 | 4 (0,9)*1 |
| 0–8 N(%) | 11(44) | 18 (78.26) | 16 (64) | 10 (77) |
| 9–12 N(%) | 13 (52) | 5 (21.74) | 8 (32) | 3 (23) |
| > 12 N(%) | 1 (4) | 0 | 1 (4) | 0 |
| Fibrosis | 4 (1,6) | 2 (0,6) | 3 (1,6) | 2 (0,6) |
| Cirrhosis N(%)*2 | 9 (36) | 5 (21.74) | 5 (20) | 3 (23) |
| Steatosis*3 | 0(0,1) | 4 (0,12) | 0 (0,3) | 0 (0,1) |
| No steatosis N(%) | 16(64) | 19 (82.61) | 13 (54.17) | 12 (92.3) |
| Mild N(%) | 9 (36) | 4 (17.39) | 10 (41.67) | 1(7.69) |
| Moderate N (%) | 0 | 0 | 0 | 0 |
| Severe N (%) | 0 | 0 | 1 (4.17) | 0 |
*1Histological activity (HAI), fibrosis and steatosis data ere expressed as median (range).
*2 Cirrhosis: Stage of fibrosis 5&6 (Ishak classification system)
*3 Steatosis: Mild: < 33% of hepatocytes affected; Moderate: 33% to 66% of hepatocytes affected; Severe: > 66% of hepatocytes affected.